433 A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04

• Bhumsuk Keam,
• Kevin Harrington,
• Ezra Cohen,
• Jean-Pascal Machiels,
• Feng Jin,
• Alison Forgie,
• Shanhong Guan,
• Jaume Pons,
• Beatriz Cirauqui,
• Sjoukje Oosting,
• Tim Welliver,
• Philip Fanning,
• Katherine Ruffner,
• Sophia Randolph

Affiliations

Bhumsuk Keam

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Kevin Harrington

Radiotherapy and Imaging, The Institute of Cancer Research, London, UK

Ezra Cohen

Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA

Jean-Pascal Machiels

Aff155 grid.7942.8000000012294713XInstitut Roi Albert II, Cliniques universitaires St-LucUniversité Catholique de Louvain Brussels Belgium

Feng Jin

5 Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

Alison Forgie

12Pfizer, San Francisco, CA, USA

Shanhong Guan

12Nektar Therapeutics, San Francisco, CA, USA

Jaume Pons

3ALX Oncology, Inc., Burlingame, CA, USA

Beatriz Cirauqui

1Institut Catala d’Oncologia, Barcelona, Spain

Sjoukje Oosting

5University of Groningen, Groningen, Netherlands

Tim Welliver

6ALX Oncology, Inc, Burlingame, CA, USA

Philip Fanning

6ALX Oncology, Inc, Burlingame, CA, USA

Katherine Ruffner

6ALX Oncology, Inc, Burlingame, CA, USA

Sophia Randolph

6ALX Oncology, Inc, Burlingame, CA, USA